Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial
Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance.
Mercurna has reached its scientific and IP milestones of the RedMedtech Discovery Fund II (RMDFII)
We are pleased to share that Mercurna has reached its scientific and IP milestones of the RedMedtech Discovery Fund II (RMDFII) by providing exciting data (in vitro and in vivo) on mCura1, Mercurna’s lead formulation for chronic kidney disease.
NTRC Precision Medicine Services is now Oncolines
As an independent company, Oncolines will now be singularly focused on offering the best precision medicine services in oncology and cancer immunotherapy for our clients.
Osteo-Pharma, a Dutch Life Sciences company committed to developing novel medical devices and pharmaceutical products to improve local bone healing, today announced a strategic research collaboration with The Chinese University of Hong Kong (“CUHK”) to advance OsteoActivator coated membranes into various fracture healing models complementary to Osteo-Pharma’s current dental OsteoActivator membrane.
Hotspot for pharmaceutical innovation
By: Brabant Development Association. The power of working together on successful drug discovery.
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
IMMUNOPRECISE ANTIBODIES LTD., a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company’s subsidiary, IPA Europe, has been granted a three-year approval for the “Crédit d’Impôt Recherche” (CIR) from the French Ministry of Higher Education and Research.
Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from SUANFARMA delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle.
Let’s join PiVitality @ Pivot Park!
Pivot Park has vitality high on its agenda and offers several ways for community members to work on their vitality. That is why we have organised vitality-related events and also developed the PiVitality online program. With these activities, we hope you become more aware of your vitality, and as a consequence, and therefore more resilient. Are you curious about what Pivot Park is organising regarding vitality? Read it in our article.
Eerste studenten lectoraat Drug Discovery in september op Pivot Park
Het lectoraat Drug Discovery van de Academie Toegepaste Biowetenschappen en Chemie in Nijmegen start in september met zijn eerste studenten op het lab op Pivot Park. Het lectoraat maakt deel uit van de HAN University of Applied Sciences. We zitten in de kelder van het RE-gebouw (0201), een lab waar we zowel biologische als chemische onderwerpen kunnen adresseren en waar ongeveer 10 tot 15 studenten tegelijk kunnen werken.
Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance.
Pharming announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals for the distribution of RUCONEST® (Conestat alfa) in the Middle East and North Africa.
Currently oNKord® is produced with cord blood from UK. The Tissue Bank License makes it possible to continue production after the Brexit transition period, to use raw materials from other countries outside the EU, for example US, in the future. They are continuing treating AML patients in the oNKord phase I/phase II clinical trial.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
